A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

5813

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Albuminuria

Interventions

DRUG: Placebo
DRUG: Canagliflozin, 100 mg
DRUG: Canagliflozin, 300 mg

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]